In a phase 2 CodeBreaK100 trial, Sotorasib monotherapy showed only modest clinical activity in KRAS G12C mutant colorectal cancer with an objective response in only 6/62 (9.7%) cases [53]. The gene discussed is KRAS; the disease is colorectal cancer.